Literature DB >> 16584136

CNS drug delivery: opioid peptides and the blood-brain barrier.

Ken A Witt1, Thomas P Davis.   

Abstract

Peptides are key regulators in cellular and intercellular physiological responses and possess enormous promise for the treatment of pathological conditions. Opioid peptide activity within the central nervous system (CNS) is of particular interest for the treatment of pain owing to the elevated potency of peptides and the centrally mediated actions of pain processes. Despite this potential, peptides have seen limited use as clinically viable drugs for the treatment of pain. Reasons for the limited use are primarily based in the physiochemical and biochemical nature of peptides. Numerous approaches have been devised in an attempt to improve peptide drug delivery to the brain, with variable results. This review describes different approaches to peptide design/modification and provides examples of the value of these strategies to CNS delivery of peptide drugs. The various modes of modification of therapeutic peptides may be amalgamated, creating more efficacious "hybrid" peptides, with synergistic delivery to the CNS. The ongoing development of these strategies provides promise that peptide drugs may be useful for the treatment of pain and other neurologically-based disease states in the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16584136      PMCID: PMC2751425          DOI: 10.1208/aapsj080109

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  177 in total

1.  Vector-mediated drug delivery to the brain.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-04-05       Impact factor: 15.470

Review 2.  Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs.

Authors:  K R Reddy
Journal:  Ann Pharmacother       Date:  2000 Jul-Aug       Impact factor: 3.154

3.  Improved delivery through biological membranes. 32. Synthesis and biological activity of brain-targeted delivery systems for various estradiol derivatives.

Authors:  M E Brewster; K S Estes; N Bodor
Journal:  J Med Chem       Date:  1988-01       Impact factor: 7.446

4.  Assessment of stereoselectivity of trimethylphenylalanine analogues of delta-opioid [D-Pen(2),D-Pen(5)]-enkephalin.

Authors:  K A Witt; C A Slate; R D Egleton; J D Huber; H I Yamamura; V J Hruby; T P Davis
Journal:  J Neurochem       Date:  2000-07       Impact factor: 5.372

5.  Increased permeability of the blood-brain barrier following experimental thermal injury of the skin. A fluorescent and electron microscopic study.

Authors:  A Basch; I G Fazekas
Journal:  Angiologica       Date:  1970

6.  Glycopeptide-membrane interactions: glycosyl enkephalin analogues adopt turn conformations by NMR and CD in amphipathic media.

Authors:  Michael M Palian; V I Boguslavsky; David F O'Brien; Robin Polt
Journal:  J Am Chem Soc       Date:  2003-05-14       Impact factor: 15.419

7.  Enhanced delivery of 5-iodo-2'-deoxyuridine to the brain parenchyma.

Authors:  M K Ghosh; A K Mitra
Journal:  Pharm Res       Date:  1992-09       Impact factor: 4.200

8.  Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice.

Authors:  C Chen; G M Pollack
Journal:  J Pharmacol Exp Ther       Date:  1998-11       Impact factor: 4.030

9.  Impairment of blood-brain barrier (BBB) in rat by immobilization stress: role of serotonin (5-HT).

Authors:  H S Sharma; P K Dey
Journal:  Indian J Physiol Pharmacol       Date:  1981 Apr-Jun

10.  Complete inactivation of target mRNA by biotinylated antisense oligodeoxynucleotide-avidin conjugates.

Authors:  R J Boado; W M Pardridge
Journal:  Bioconjug Chem       Date:  1994 Sep-Oct       Impact factor: 4.774

View more
  24 in total

1.  Isolation and characterization of glycosylated neuropeptides.

Authors:  Yang Liu; Qinjingwen Cao; Lingjun Li
Journal:  Methods Enzymol       Date:  2019-08-12       Impact factor: 1.600

2.  Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists.

Authors:  Takashi Yamamoto; Padma Nair; Neil E Jacobsen; Josef Vagner; Vinod Kulkarni; Peg Davis; Shou-Wu Ma; Edita Navratilova; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

3.  Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrier.

Authors:  Patrick T Ronaldson; Jessica D Finch; Kristin M Demarco; Colleen E Quigley; Thomas P Davis
Journal:  J Pharmacol Exp Ther       Date:  2010-12-02       Impact factor: 4.030

4.  Self-assembled polymersomes conjugated with lactoferrin as novel drug carrier for brain delivery.

Authors:  Yuan Yu; Zhiqing Pang; Wei Lu; Qi Yin; Huile Gao; Xinguo Jiang
Journal:  Pharm Res       Date:  2011-10-07       Impact factor: 4.200

5.  Opioid Peptides: Potential for Drug Development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  Drug Discov Today Technol       Date:  2012

Review 6.  Modulation of the cannabinoid receptors by hemopressin peptides.

Authors:  Martha G Bomar; Amit K Galande
Journal:  Life Sci       Date:  2012-08-01       Impact factor: 5.037

7.  sCD44 internalization in human trabecular meshwork cells.

Authors:  Michael J Nolan; Tomoyo Koga; Loyal Walker; Ryan McCarty; Algis Grybauskas; Michael C Giovingo; Kevin Skuran; Paulius V Kuprys; Paul A Knepper
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

Review 8.  Targeted drug delivery to treat pain and cerebral hypoxia.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

9.  Factor V activator from Daboia russelli russelli venom destabilizes β-amyloid aggregate, the hallmark of Alzheimer disease.

Authors:  Payel Bhattacharjee; Debasish Bhattacharyya
Journal:  J Biol Chem       Date:  2013-08-28       Impact factor: 5.157

Review 10.  Peptide kappa opioid receptor ligands: potential for drug development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.